New drug targets Cancer's 'Extra DNA' in early trial
NCT ID NCT05827614
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This early-phase study tests an experimental oral drug, BBI-355, in people with advanced solid tumors (like certain breast, ovarian, lung, and other cancers) that have extra copies of certain genes (oncogene amplifications). The study aims to find the safest dose and see if BBI-355 works alone or combined with other targeted therapies. About 85 participants whose cancer has progressed after standard treatments will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK (HNSCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
Lake Mary, Florida, 32746, United States
-
HealthONE
Denver, Colorado, 80218, United States
-
MD Anderson Cancer Center
Houston, Texas, 77054, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
NEXT Oncology - Dallas
Irving, Texas, 75039, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarcoma Oncology
Santa Monica, California, 90403, United States
-
The University of Kansas
Fairway, Kansas, 66205, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
University of Washington, Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.